BioLife Solutions Inc
$ 26.60
-0.23%
11 Jun - close price
- Market Cap 1,346,022,000 USD
- Current Price $ 26.60
- High / Low $ 27.27 / 26.35
- Stock P/E N/A
- Book Value 7.62
- EPS -0.24
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.03 %
- 52 Week High 29.62
- 52 Week Low 17.86
About
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Analyst Target Price
$32.30
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-03 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-08 |
| Reported EPS | 0.0435 | 0.039 | 0.042 | -0.33 | 0.0355 | -0.016 | -0.0175 | -0.5 | -0.23 | -0.3 | -0.3 | -0.23 |
| Estimated EPS | 0.0167 | -0.0038 | -0.0113 | -0.03 | -0.035 | -0.0567 | -0.09 | -0.14 | -0.28 | -0.34 | -0.37 | -0.2 |
| Surprise | 0.0268 | 0.0428 | 0.0533 | -0.3 | 0.0705 | 0.0407 | 0.0725 | -0.36 | 0.05 | 0.04 | 0.07 | -0.03 |
| Surprise Percentage | 160.479% | 1126.3158% | 471.6814% | -1000% | 201.4286% | 71.7813% | 80.5556% | -257.1429% | 17.8571% | 11.7647% | 18.9189% | -15% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BLFS
2026-06-10 20:39:34
BioLife Solutions CFO Troy Wichterman reported a routine tax-related disposition where 1,026 shares of common stock were withheld to cover tax obligations from vested restricted stock units. This transaction was not an open-market sale, and Wichterman retains a substantial equity position, holding 215,030 shares of BioLife Solutions common stock. The event reflects a compensation-related, non-discretionary transaction.
2026-06-10 20:39:34
BioLife Solutions Inc.'s Chief Marketing Officer, Todd Berard, reported a tax-related disposition of 356 shares of Common Stock to cover tax withholding obligations upon the release of restricted stock units. This transaction does not represent an open-market sale, and Berard's direct holdings remain largely unchanged at 163,412 shares. The filing, a Form 4, indicates a neutral impact and sentiment regarding the insider trading activity.
2026-06-10 20:39:34
BIOLIFE SOLUTIONS INC's EVP & Chief Scientific Officer, Mathew Aby J., had 627 common shares withheld on June 8, 2026, at $26.10 per share. This transaction was a routine tax-withholding disposition to cover obligations arising from the release of restricted stock units, not an open-market sale. Following this event, Mathew Aby J. directly holds 389,540 shares of common stock.
2026-06-04 23:09:29
The US market has increased by 26% over the past year, and this article highlights three undervalued stocks based on cash flows: BioLife Solutions (BLFS), LPL Financial Holdings (LPLA), and Reddit (RDDT). Each company is trading at a significant discount to its estimated fair value and is projected to have strong future earnings growth. Detailed analyses for each stock are provided, including current price, fair value, and growth forecasts.
2026-06-04 22:10:08
Casdin Capital, LLC and affiliated entities have filed a Schedule 13G, disclosing a shared beneficial ownership of 4,757,165 shares of BioLife Solutions Inc. (BLFS) common stock, representing 9.7% of the class. The filing, dated June 4, 2026, indicates that these shares are held by advisory clients, including Casdin Partners Master Fund, L.P., and that the reporting persons disclaim sole voting or dispositive power. The disclosure highlights a passive investment stake, not intended for control.
2026-06-04 11:10:12
MarketBeat provides an overview of BioLife Solutions' (BLFS) SEC filings, noting over 1,006 documents submitted since 2017. The article details recent filings such as a Form SCHEDULE 13G on June 4, 2026, a Form 4 on May 21, 2026, and an 8-K on June 3, 2026. It also explains the significance of different SEC filing types like 10-K, 10-Q, 8-K, and Form 4 for investors.
